Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 39,500 shares, an increase of 65.3% from the October 15th total of 23,900 shares. Approximately 9.1% of the company’s shares are short sold. Based on an average daily trading volume, of 58,100 shares, the days-to-cover ratio is presently 0.7 days.

Cadrenal Therapeutics Stock Performance

Shares of CVKD opened at $17.73 on Wednesday. The company has a 50-day moving average price of $13.09. Cadrenal Therapeutics has a one year low of $5.40 and a one year high of $32.55. The firm has a market cap of $18.94 million, a P/E ratio of -2.68 and a beta of 1.52.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their price objective on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.